NHS London Procurement Partnership has launched a pre-market engagement exercise for a new framework covering digital office and transformation solutions, with an estimated value of £735 million. The initiative is intended to simplify how NHS and wider public sector organisations procure digital technologies and services, and to extend the range of solutions available under a single contracting vehicle.

This is the second round of engagement. The first took place in October 2025, when NHS LPP set out initial plans for what would become the Digital Office and Transformation Solutions framework, known as DOTS. That consultation covered a broad set of services including document management software, data storage, business intelligence tools, video conferencing, software development and internet and support services.

The second round builds on that foundation. NHS LPP has stated that the framework will support adoption of technologies enabling workflow optimisation, automation, AI-enabled solutions, digital document management, analytics, infrastructure modernisation and enterprise-wide digital strategies. The shift in framing from document solutions to operational transformation reflects the scale of digital change NHS organisations are being expected to manage.

Organisations wishing to participate in the pre-market engagement have until 3 July 2026 to respond. A formal tender notice is expected around the end of August 2026, with the contract period estimated to run from February 2027 through to September 2034, a span of more than seven years.

The procurement arrives at a moment when the regulatory environment for health technology, particularly AI, remains unsettled. The Medicines and Healthcare products Regulatory Agency has published findings from the National Commission into the Regulation of AI in Healthcare, and the results make uncomfortable reading for those overseeing the sector. Almost three-quarters of respondents disagreed or strongly disagreed that the current regulatory framework is sufficient to ensure safety and performance standards. Sixty-one per cent took the same view on data governance and data privacy. The same proportion said requirements for clinical evidence are insufficient, and 65 per cent identified post-market surveillance as an area needing significant improvement.

The MHRA has responded in part by announcing plans for a regulatory AI sandbox, funded by the Regulatory Innovation Office. The sandbox is designed to allow AI tools to be tested for their potential to predict how medicines are absorbed and processed, and whether they may cause harm. It will also be used to inform the agency's own understanding of whether AI can reliably support decisions about the safety of new medicines. The initiative is exploratory in character, intended to generate evidence about AI's role in medicines regulation rather than to deploy tools at scale.

Taken together, the DOTS framework and the MHRA's regulatory moves reflect the dual pressure NHS bodies are facing: to accelerate the adoption of digital and AI technologies across clinical and operational settings, and to do so within governance structures that, by the MHRA's own findings, are not yet adequate for the task. The gap between procurement ambition and regulatory readiness is one the sector will need to address over the life of a contract that runs to 2034. How NHS organisations navigate that gap, and whether frameworks like DOTS provide genuine support or simply create new procurement complexity, will become clearer once the tender process begins later this year.